Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-353
- Development stage
- Preclinical
- Lead developer
- NeoTX Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
NTX-353 is a preclinical-stage tumor-targeted superantigen (TTS) biologic being developed by NeoTX Therapeutics in collaboration with the Dana-Farber Cancer Institute for the treatment of glioblastoma multiforme (GBM). The TTS platform utilizes a fusion protein comprising a tumor-targeting moiety and a bacterial superantigen. This approach is designed to induce a potent T-cell mediated immune response directly within the tumor microenvironment by bypassing the requirement for specific antigen presentation. By coating tumor cells with superantigens, NTX-353 aims to activate a large population of T cells to recognize and destroy the glioblastoma cells, potentially overcoming the highly immunosuppressive nature of central nervous system tumors.
- Other names
- TTS for GBM
02
Targets
MHC II (Major histocompatibility complex class II receptor)TRBV (T-cell receptor beta variable)γδ TCR (T-cell receptor)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on NTX-353.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-353.